NYSEAMERICAN : PLX

Protalix BioTherapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.59 USD (Oct 30, 2026, 10:12 AM EDT) · Market cap 208.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Details

NameProtalix BioTherapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees226
Founded1993
Ipo Date1998-05-15
CeoDror Bashan
CountryUnited States
ExchangeNYSEAMERICAN
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS74365A3095
Cusip74365A309
Cik0001006281
Sic2836

Key executives

NameTitle
Dror BashanPresident, Chief Executive Officer and Director
Gilad MamlokSenior Vice President, Chief Financial Officer Treasurer and Secretary
Yaron Naos B.Sc., MBASVice President and Chief Operating Officer
Yael FellousVice President of Human Resources

Contact

Address2 University Plaza, Suite 100, Hackensack, New Jersey 07601, United States
Phone201 696 9345
Websitehttps://www.protalix.com